COMMUNIQUÉS West-GlobeNewswire

[Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong 2025 results with 7% sales growth
29/01/2026
Group sales grew by 7% 1 at constant exchange rates (CER; 2% in CHF), driven by strong demand for medicines and diagnostic solutions. Sales in the fourth quarter increased by 8%, reflecting the positive momentum. [...]
Ipsen nominates Peter Guenter to its Board of Directors
29/01/2026
PARIS, FRANCE, 29 January 2026 - Ipsen (Euronext: IPN; ADR: IPSEY) announced today the co-optation of Peter Guenter to its Board as a Director, effective January 28, 2026, further to the vacancy of Mr. Henri Beaufour’s [...]
OSE Immunotherapeutics sélectionne la pouchite chronique et l’hidradénite suppurée comme nouvelles indications clés pour Lusvertikimab
29/01/2026
OSE Immunotherapeutics sélectionne la pouchite chronique et l’hidradénite suppurée comme nouvelles indications clés pour Lusvertikimab Développement basé sur un fort rationnel biologique de l’IL-7R La pouchite chronique [...]
Press release: 2025: strong sales and EPS growth. Continued profitable growth expected in 2026
29/01/2026
2025: strong sales and EPS growth. Continued profitable growth expected in 2026 Paris, January 29, 2026 Q4 sales growth of 13.3% at CER 1 and business earnings per share (EPS) 2 of €1.53 Pharma launches increased sales [...]
Interim Results for the six months ended 31 October 2025
29/01/2026
OXFORD, United Kingdom, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Scancell Holdings plc (AIM: SCLP), the developer of ImmunoBody ® and Moditope ® active immunotherapies to treat cancer, today announces a business update and [...]
Ipsen nomme Peter Guenter au sein de son Conseil d’Administration
29/01/2026
PARIS, FRANCE, 29 janvier 2026 - Ipsen (Euronext: IPN; ADR: IPSEY) annonce aujourd'hui la cooptation de Peter Guenter au sein de son Conseil d'Administration en tant qu'Administrateur, à compter du 28 janvier 2026, [...]
OSE Immunotherapeutics Selects Chronic Pouchitis and Hidradenitis Suppurativa as New Key Indications for Lusvertikimab
29/01/2026
OSE Immunotherapeutics Selects Chronic Pouchitis and Hidradenitis Suppurativa as New Key Indications for Lusvertikimab Development built on strong IL-7R biological rationale Chronic Pouchitis offers a capital-efficient [...]
Enterome appoints leading hematologist and IFLI Executive Partner Mehrdad Mobasher, M.D., M.P.H., to its Board of Directors
29/01/2026
Dr. Mobasher held several executive roles in industry, most recently CMO at BeiGene IFLI contributed up to $9 million to Enterome’s private funding round in 2025 Enterome has announced a series of encouraging clinical [...]
Communiqué de presse : 2025 : année de forte croissance du chiffre d’affaires et du BNPA. Poursuite d’une croissance rentable attendue en 2026
29/01/2026
2025 : année de forte croissance du chiffre d’affaires et du BNPA. Poursuite d’une croissance rentable attendue en 2026. Paris, le 29 janvier 2026 Ventes du T4 en progression de 13,3 % à TCC 1 et BNPA 2 des activités de [...]
Psyence BioMed Announces Effective Date for 1-for-6.25 Reverse Stock Split
29/01/2026
NEW YORK, Jan. 28, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“ Psyence BioMed ” or the “ Company ”), today announced the effective date of its 1-for-6.25 share consolidation (reverse stock split) [...]
Ryoncil® Net Revenues Increase for the Quarter to US$30M
29/01/2026
Activity Report for Quarter Ended December 31, 2025 (Appendix 4C) NEW YORK, Jan. 28, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory [...]
TomorrowsRx Telehealth Service Outlines Prescription Access for Compounded Semaglutide and Advanced Tirzepatide Formulations
29/01/2026
An informational overview examining what consumers often consider when researching telehealth-based prescription weight management treatment access through physician-supervised platforms SAN MARCOS, CA, Jan. 28, 2026 ( [...]
Elevar Therapeutics Submits New Drug Application to FDA for Lirafugratinib as Second-Line Treatment Option for Cholangiocarcinoma
28/01/2026
FORT LEE, N.J., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Co., Ltd. and a fully integrated biopharmaceutical company dedicated to elevating treatment experiences and [...]
Serina Therapeutics Announces FDA Clearance of IND Application for SER-252 for the Treatment of Advanced Parkinson’s disease
28/01/2026
- Phase 1b clinical site start-up and regulatory activities in Australia underway to support the global registrational program - HUNTSVILLE, AL, Jan. 28, 2026 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina” or [...]
STERIS Announces Dividend of $0.63 per share
28/01/2026
DUBLIN, IRELAND, Jan. 28, 2026 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that the Company will distribute a quarterly dividend of $0.63 per share. The dividend is payable on [...]
Park Dental Partners Expands Presence in Arizona with Addition of Ironwood Dental
28/01/2026
MINNEAPOLIS, Jan. 28, 2026 (GLOBE NEWSWIRE) -- Park Dental Partners, Inc. (NASDAQ: PARK) (the Company), a leading dental resource organization, announced that on January 23, 2026, Ironwood Dental, located in Tucson, [...]
Senseonics Holdings, Inc. to Participate at the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference
28/01/2026
GERMANTOWN, Md., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose [...]
Amneal Pharmaceuticals Added to S&P SmallCap 600® Index
28/01/2026
BRIDGEWATER, N.J., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) today announced that it has been added to the S&P SmallCap 600 ® Index. The inclusion will [...]
Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides a Corporate Update
28/01/2026
First patients dosed in DAYBreak™ registrational program for bexobrutideg in relapsed/refractory CLL Presented Phase 1 results at ASH 2025 that support bexobrutideg’s potential best-in-class profile in relapsed/ [...]

Pages